Literature DB >> 783197

Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease. A hemodynamic, volumetric, and metabolic study in patients without heart failure.

H DeMots, S H Rahimtoola, E L Kremkau, W Bennett, D Mahler.   

Abstract

The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man. We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure. Because the protocol was long and involved interventions which might affect the determinations, we also studied in nine patients using an identical protocol except that ouabain administration was omitted. Left ventricular end-diastolic pressure and left ventricular end-diastolic volume fell in each patient given ouabain, even though they were initially elevated in only two patients. Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed. The maximum velocity of contractile element shortening increased from 1.68+/-0.11 ml/s to 2.18+/-0.21 muscle-lengths/s (P less than 0.05) and is consistent with an increase in contractility. No significant change in these parameters occurred in the control patients. No significant change in myocardial oxygen consumption occurred after ouabain administration but this may be related to a greater decrease in mean arterial pressure in the ouabain patients than in the control patients. We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal. Though this fall would be associated with a decrease in wall tension, and, therefore, of myocardial oxygen consumption, it may not be of sufficient magnitude to prevent a net increase in myocardial oxygen consumption. Nevertheless, compensatory mechanisms prevent a deterioration of resting myocardial metabolism.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 783197      PMCID: PMC333185          DOI: 10.1172/JCI108474

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  STUDIES ON DIGITALIS. X. EFFECTS OF OUABAIN ON FOREARM VASCULAR RESISTANCE AND VENOUS TONE IN NORMAL SUBJECTS AND IN PATIENTS IN HEART FAILURE.

Authors:  D T MASON; E BRAUNWALD
Journal:  J Clin Invest       Date:  1964-03       Impact factor: 14.808

2.  THE EFFECT OF ANGIOCARDIOGRAPHIC CONTRAST MEDIUM ON CIRCULATORY DYNAMICS IN MAN. CARDIAC OUTPUT DURING ANGIOCARDIOGRAPHY.

Authors:  R BROWN; S H RAHIMTOOLA; G D DAVIS; H J SWAN
Journal:  Circulation       Date:  1965-02       Impact factor: 29.690

3.  Myocardial lactate and pyruvate metabolism.

Authors:  N KRASNOW; W A NEILL; J V MESSER; R GORLIN
Journal:  J Clin Invest       Date:  1962-11       Impact factor: 14.808

4.  Studies on digitalis. VI. Reduction of the oxygen debt after exercise with digoxin in cardiac patients without heart failure.

Authors:  R L KAHLER; R H THOMPSON; E R BUSKIRK; R L FRYE; E BRAUNWALD
Journal:  Circulation       Date:  1963-03       Impact factor: 29.690

5.  [Quantitative determination of L-(+)lactic acid with lactic dehydrogenase].

Authors:  F H BRUNS; H D HORN
Journal:  Biochim Biophys Acta       Date:  1956-08

6.  STUDIES ON DIGITALIS. IX. EFFECTS OF OUABAIN ON THE NONFAILING HUMAN HEART.

Authors:  D T Mason; E Braunwald
Journal:  J Clin Invest       Date:  1963-07       Impact factor: 14.808

7.  STUDIES ON DIGITALIS. IV. OBSERVATIONS IN MAN ON THE EFFECTS OF DIGITALIS PREPARATIONS ON THE CONTRACTILITY OF THE NON-FAILING HEART AND ON TOTAL VASCULAR RESISTANCE.

Authors:  E Braunwald; R D Bloodwell; L I Goldberg; A G Morrow
Journal:  J Clin Invest       Date:  1961-01       Impact factor: 14.808

8.  Hemodynamic changes attending angiocardiography.

Authors:  J D Bristow; G A Porter; F E Kloster; H E Griswold
Journal:  Radiology       Date:  1967-05       Impact factor: 11.105

9.  Comparison of the effects of 1-norepinephrine, angiotensin, dipyridamole, digitoxin, and reserpine on the regional distribution of coronary blood flow.

Authors:  W D Love; R S Munford; R E Abraham
Journal:  J Lab Clin Med       Date:  1965-09

10.  Estimation of left ventricular volume by one-plane cineangiography.

Authors:  D G Greene; R Carlisle; C Grant; I L Bunnell
Journal:  Circulation       Date:  1967-01       Impact factor: 29.690

View more
  6 in total

1.  Haemodynamic and coronary actions of ouabain during coronary infusion.

Authors:  M Zimpfer; W Schütz; G Raberger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-08       Impact factor: 3.000

2.  Direct assessment of cardiac function.

Authors:  J Hamer
Journal:  Br J Clin Pharmacol       Date:  1978-07       Impact factor: 4.335

3.  Pharmacodynamic effects of ouabain following single sublingual and intravenous doses in normal subjects.

Authors:  G G Belz; J Matthews; U Sauer; H Stern; B Schneider
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Relationship between myocardial uptake and actions in heart failure of methyldigoxin.

Authors:  R Hayward; H Greenwood; J Stephens; J Hamer
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

Review 5.  Combination of positive inotropic and vasodilating substances in congestive heart failure.

Authors:  I Cantelli; D Bracchetti
Journal:  Cardiovasc Drugs Ther       Date:  1988-05       Impact factor: 3.727

Review 6.  Research Progress in Pharmacological Activities and Applications of Cardiotonic Steroids.

Authors:  Junwei Ren; Xinyuan Gao; Xi Guo; Ning Wang; Xin Wang
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.